Dublin, Ireland, 6th November 2025 – Johnson & Johnson Innovative Medicine announced today that TALVEY®▼ (talquetamab) has been approved for reimbursement in Ireland as a monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma (RRMM) who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy. The announcement follows conditional marketing authorisation (CMA) in 2023 which was supported by positive results from the Phase 1/2 MonumenTAL-1 study evaluating the safety and efficacy of talquetamab in patients with RRMM.[1]
Multiple myeloma remains an incurable blood cancer, with nearly all patients relapsing and requiring subsequent therapy.[2],[3] As the disease progresses, relapses for patients become more aggressive with each new line of therapy, and remissions become progressively shorter. Approximately, 380 people are diagnosed with multiple myeloma each year in Ireland.[4] While Irish figures show that the five-year net survival for someone diagnosed with MM has increased from 30% in the mid-1990s to 60% by 2020, the unmet need for those with RRMM remains.[5]
For verified healthcare professionals
Log in or register for free to read this article. HPN is for healthcare professionals, so new accounts are verified by our team.
